What Extent of Pancreatic Resection Do Patients with MEN-1 Require?
Abstract
Context The surgical management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1 (MEN-1) is controversial and complicated by the fact that these tumors are frequently multifocal. The degree of tumor resection is determined by weighing the risk of malignancy or tumor recurrence against the risks of endocrine/exocrine insufficiency with complete gland removal. Methods A retrospective review was performed identifying 4 patients with MEN-1 and pancreatic endocrine tumors treated with pancreatic resection over a 2-year period at our institution. Results Mean age at operation was 35 years. Surgical approach was determined by size of tumor(s) and presence of multifocality. MRI and EUS were performed in all patients. While EUS identified a greater number of tumors when compared to MRI (median 5 versus 1), both studies grossly underestimated the total number of tumors found on final pathology. Three patients underwent laparoscopic total pancreatectomy for multifocal disease with diffuse pancreatic involvement, finding a median of 12 tumors. One patient underwent laparoscopic subtotal pancreatectomy for a presumed single pancreatic tail mass, but was found to have multifocal disease on final pathology consisting of 7 tumors. The average number of tumors found on final pathology was 13.5 with an average size of 2.6 cm. The median number of lymph nodes analyzed was 14. Diffuse, multifocal disease was present in all 4 patients. No major postoperative complications were observed. Conclusion In patients with MEN-1 and pancreatic endocrine tumors, preoperative workup underestimates extent of disease and total pancreatectomy should be considered for complete tumor removal.
Image: Mayo Clinic Hospital, Jacksonville. FL, USA.
Downloads
References
Chandrasekharappa S, Guru S, Manickamp P, et al. Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 1997;276:404-407.
Guo S, Sawicki M. Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type 1. Mol Endocrin 2001;15(10):1653-1664.
Kang C, Park S, Kim K, Choi J, et al. Surgical experiences of functioning neuroendocrine neoplasm of the pancreas. Yonsei Medial Journal 2006;47(6):833-839.
Skogseid B, Eriksson B, Lundqvist G, et al. Multiple endocrine neoplasia type 1: a 10 year prospective screening study in four kindreds. J Clin Endocrinol Metab 1991;73:281-287.
Skogseid B, Rashad J, Akerstrom G. Pancreatic endocrine tumors in multiple endocrine neoplasia type 1. In: Doherty GM, Skogseid B, editors. Surgical endocrinology. Philadelphia: Lippincott Williams and Wilkins; 2001. p 511-524.
Lairmore T, Piersall L, DeBenedetti M, et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1 ). Ann Surg 2004;239;637-645.
Brandi M, Gagel R, Angelli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and 2. J Clin Endocrin Metab 2001;86:5658-5671.
Lairmore T, Chen V, DeBenedetti M, Gillanders W, et al. Duodenopancreatic Resections in Patients with Multiple Endocrine Neoplasia Type 1. Annals of Surgery 2000; 231 (6): 909-918.
Vasen H, Lamers C, Lips C. Screening for the multiple endocrine neoplasia syndrome type 1: a study of 11 kindreds in The Netherlands. Arch Int Med. 1989;149:2717-2722.
Skogseid B, Eriksson B, Lundqvist G, et al. Multiple endocrine neoplasia type 1: a 10 year prospective screening study in four kindreds. J Clin Endocrin Metab 1991;73:281-287.
Kouvaraki M, Shapiro S, Cote G, et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 2006; 30: 643-653.
Ballard FB, Hartstock RJ. Familial endocrine adenoma-peptic ulcer complex. Medicine (Baltimore) 1964; 43:481-516.
Gibril F, Chen Y, Schrump D, et al. Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrin Metab 2003;88(3):1066-1081.
Marx S, Spiegel A, Skarulis M, et al. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 1998;129(6):484-494.
Brandi M, Gagel R, Angeli A et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrin Metab 2001;86(12):5658-5671.
Burgess J, Greenaway T, Shepherd J. Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1. J Inten Med 1998;243(6):465-470.
Darling T, Skarulis M, Steinberg S, et al. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermat 1997;133(7)853-857.
Duh Q, Hybarger C, Geist R, et al. Carcinoids associated with multiple endocrine neoplasia syndromes. Am J Surg 1987;154(1):142-148.
Metz D. Multiple endocrine neoplasia type 1. Semin Gastrointest Dis 1995;6(2):56-66.
Trump D, Farren B, Wooding C, et al. Clinical studies of multiple endocrine neoplasia type 1. Q J Med 1996;89:653-669.
Schussheim D, Skarulis M, Agarwal S, et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 2001;12:173-178.
Jensen R. Pancreatic endocrine tumors: recent advances. Ann Oncol 1999;10:170-176.
Gauger P, Doherty G, Broome J, et al. Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms. Surgery 2009; 146(4): 801-808.
Waldman J, Fendrich V, Habbe N, Bartsch D, et al. Screening of patients with multiple endocrine neoplasia type 1: A critical analysis of its value. World J Surg 2009;33:1208-1218.
Dralle H, Krohn S, Karges W, Boehm B, et al. Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg 2004;28:1248-1260.
Majewski J, Wilson D. The MEN1 syndrome: an all or none phenomenon? Surgery 1979; 86:475-484.
Thompson N, Lloyd R, Nishiyama R, et al. MEN 1 pancreas: a histological and immunohistochemical study. World J Surg 1984;8:561-574.
Marini F, Falchetti A, Luzi E, et al. Multiple Endocrine Neoplasia Type 1 (MEN1) Syndrome. [July 18, 2008 [updated [August 9, 2008]. In: Riegert-Johnson DL, Boardman LA, Hefferon T, Roberts M, eds. Cancer Syndromes (Internet). Bethesda (MD): National Center for Biotechnology Information ; 2009.
Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000;62:51-58.
Jensen R. Natural history of digestive endocrine tumors. In: Mignon M, Colombel J, eds. Recent advances in pathophysiology and management of inflammatory bowel disease and digestive endocrine tumors. Paris, France: John Libbey Eurotext Publishing Co;1999:192-219.
Norton J. Neuroendocrine tumors of the pancreas and duodenum. Curr Prob Surg 1994;31:71-156.
Wilkinson S, The B, Davey K, et al. Cause of death in multiple endocrine neoplasia type 1. Arch Surg 1993; 128: 683.
Doherty G, Olson J, Frisella M, et al. Lethality of multiple endocrine neoplasia type 1. World J Surg 1997; 22: 581-586.
Weber HC, Venzon DJ, Lin JT, Fishbein VA, Orbuch M, Strader DB, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108:1637-49. [PMID 7768367]
Solica E, Kloeppel G, Sobin L. World Health Organization: International Histological Classification of Tumours: Histological Typing of Endocrine Tumors. Berlin: Springer, 2000.
Weber H, Venzon D, Lin J, et al. Determinant of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology. 1995;108:1637-1649.
Lowney J, Frisella M, Lairmore T, Doherty G. Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size. Surgery 1998; 124: 1043-1049.
Dean P, van Heerden J, Farley D, et al. Are patients with multiple endocrine neoplasia type 1 prone to premature death? World J Surg 2000;24:1437-1441.
Ruszniewski P, Podevin P, Cadiot G, et al. Clinical, anatomic, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type 1 multiple endocrine neoplasia. Pancreas 1993;8:295-304.
Norton J, Alexander H, Fraker D, et al. Comparison of surgical results in patient with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001;234:495-505.
Doppman J. Multiple endocrine neoplasia syndromes. A nightmare for the endocrinologic radiologist. Sem Roentgenol 1985; 20: 7-16.
Stauffer JA, Nguyen J, Heckman M, Grewal M, et al. Patient outcomes after total pancreatectomy: a single centre contemporary experience. HPB 2009;11(6):483-492.
Ichikawa T, Peterson MS, Federle MP et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 2000; 216:163-171.
Thoeni RF, Mueller-Lisse UG, Chan R, Do NK, Shyn PB Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 2000; 214:483-490.
Botsios D, Vasliliadis K, Tsalis K, Iordanidis F, et al. Management of nonfunctioning pancreatic endocrine tumors in the context of multiple endocrine neoplasia type 1 syndrome. J Gastrointestin Liver Dis 2007;16(3):257-262.
Zimmer T, Stolzel U, Bader M, et al. Endoscopic ultrasonography and somatostain receptor scintigraphy in preoperative localization of insulinomas and gastrinomas. Gut 1996;39:562-568.
Proye C, Malvaux P, Pattou F, et al. Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery 1998;124:1134-1143.
Mutch M, Frisella M, DeBenedetti M, et al. Pancreatic polpeptide is a useful plasma marker for radiographically evident pancreatic islet cell tumors in patients with multiple endocrine neoplasia type 1. Surgery 1997;122:1012-1019.
Goudet P, Calendar A, Cougard P, et al. Multiple endocrine neoplasia type 1 r Werner syndrome: what is important to know about surgery of a rare disease. Ann Chir 2002;127:591-599.
GTE. Recommendation booklet on MEN1. 2004.
Doherty G. Multiple endocrine neoplasia type 1: duodenopancreatic tumors. Surg Oncol 2003;12:135-143.
Akerstrom G, Hessman O, Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN1. Langenbecks’ Arch Surg 2002;386:558-569.
Doherty G, Thompson N. Multiple endocrine neoplasia type 1: duodenopancreatic tumors. J Intern Med 2003;253:590-598.
Dralle H, Krohn S, Karges W, et al. Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg 2004;28:1248-1260.
Hausman M, Thompson N, Gauger P, et al. The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery 2004;136:1205-1211.
Skogseid B, Eriksson B, Lundqvist G, et al. Multiple endocrine neoplasia type 1: a 10 year prospective screening study in four kindreds. J Clin Endocrinol Metab 1991;73:281-287.
Skogseid B, Grama D, Rastad J, et al. Operative tumour yield obviates preoperative pancreatic tumour localization in multiple endocrine neoplasia type 1. J Intern Med 1995;238:281-288.
Skogseid B, Aberg K, Akerstrom G, et al. Experience with multiple endocrine neoplasia type 1 screening. J Intern Med 1995;238:255-261.
Skogseid B, Aberg K, Akerstrom G, et al. Limited tumour involvement found at multiple endocrine neoplasia type 1 pancreatic exploration: can it be predicted by preoperative tumor localization. World J Surg 1998;22:673-678.
Stauffer JA, Rosales-Velderrain A, Goldberg RF, et al. Surrogate oncologic markers for long term survival are improved with the use of minimal access surgery for pancreatic cancer. HPB 2012;14 (Supplement 1), 1-91, page 75.
Copyright (c) 2014 Cameron David Adkisson, John A Stauffer, Steven P Bowers, Massimo Raimondo, Michael B Wallace, Douglas L Riegert-Johnson, Horacio J Asbun
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.